|
|
Vaccine Detail
|
Recombinant Fowlpox-B7.1 Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant Fowlpox-B7.1 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007036
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- CD80
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: A fowlpox virus is used as vector to deliver and induce B7-1 expression on antigen presenting cells (Arlen et al., 2003).
- Description: This is for Solid Tumors (NCT00030693). A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the stimulatory molecule transgene B7-1. Recombinant fowlpox-B7.1 (rF-B7.1) vaccine may enhance antigen presentation and activate antitumoral cytotoxic T-cells (NCIT_C2666).
|
| Host Response |
|
|
| References |
Arlen et al., 2003: Arlen PM, Gulley JL, Palena C, Marshall J, Schlom J, Tsang KY. A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1. Journal of immunological methods. 2003; 279(1-2); 183-192. [PubMed: 12969559].
NCIT_C2666: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2666]
NCT00030693: [https://clinicaltrials.gov/ct2/show/NCT00030693?term=Recombinant+Fowlpox-B7.1+Vaccine&rank=1]
|
|
